Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHI NASDAQ:KTTA NASDAQ:KZIA NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$0.53+0.7%$0.60$0.50▼$2.60$21.48M0.9942,266 shs4,604 shsKTTAPasithea Therapeutics$0.81-3.2%$0.77$0.28▼$2.06$20.28M0.22346,252 shs46,595 shsKZIANovogen$14.15+5.5%$9.24$3.19▼$17.40$23.34M2.22221,986 shs85,182 shsRDHLRedhill Biopharma$1.00-1.0%$0.89$0.71▼$3.31$5.19M5.05342,443 shs9,261 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma-0.25%-4.35%-18.56%-24.18%-71.94%KTTAPasithea Therapeutics-1.16%+20.92%+5.26%+15.86%-25.66%KZIANovogen-3.11%-1.69%+39.40%+131.61%+311.98%RDHLRedhill Biopharma-1.55%-6.97%+26.75%-5.23%-47.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$0.53+0.7%$0.60$0.50▼$2.60$21.48M0.9942,266 shs4,604 shsKTTAPasithea Therapeutics$0.81-3.2%$0.77$0.28▼$2.06$20.28M0.22346,252 shs46,595 shsKZIANovogen$14.15+5.5%$9.24$3.19▼$17.40$23.34M2.22221,986 shs85,182 shsRDHLRedhill Biopharma$1.00-1.0%$0.89$0.71▼$3.31$5.19M5.05342,443 shs9,261 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma-0.25%-4.35%-18.56%-24.18%-71.94%KTTAPasithea Therapeutics-1.16%+20.92%+5.26%+15.86%-25.66%KZIANovogen-3.11%-1.69%+39.40%+131.61%+311.98%RDHLRedhill Biopharma-1.55%-6.97%+26.75%-5.23%-47.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/AKTTAPasithea Therapeutics 1.67Reduce$3.00269.00% UpsideKZIANovogen 2.50Moderate Buy$21.0048.45% UpsideRDHLRedhill Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest RDHL, KZIA, KTTA, and CPHI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RDHLRedhill Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$4.14M5.18N/AN/A$0.70 per share0.76KTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/AKZIANovogen$30K778.03N/AN/A($5.34) per share-2.65RDHLRedhill Biopharma$290K17.90N/AN/A$0.83 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08M-$0.75N/AN/AN/A-85.56%-63.93%-31.42%N/AKTTAPasithea Therapeutics-$20.43M-$3.57N/AN/AN/AN/A-85.48%-77.42%5/21/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/ARDHLRedhill Biopharma-$430K$1,046.750.00N/AN/AN/AN/AN/AN/ALatest RDHL, KZIA, KTTA, and CPHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AKTTAPasithea Therapeutics-$3.40N/AN/AN/A$0.30 millionN/A3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/A3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/A2/14/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/A$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26KTTAPasithea TherapeuticsN/A11.3511.35KZIANovogenN/A2.87N/ARDHLRedhill BiopharmaN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/AKTTAPasithea Therapeutics23.92%KZIANovogen30.89%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma6.40%KTTAPasithea Therapeutics2.00%KZIANovogen1.00%RDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma25040.52 million15.92 millionNot OptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataRDHLRedhill Biopharma2105.19 million4.84 millionNo DataRDHL, KZIA, KTTA, and CPHI HeadlinesRecent News About These CompaniesRedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's DiseaseApril 30, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational HighlightsApril 27, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical ...April 23, 2026 | finanznachrichten.deRedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026April 22, 2026 | prnewswire.comJoint U.S. Commercialization of RedHill's Talicia® CommencesFebruary 25, 2026 | prnewswire.comRedhill Biopharma stock soars on GLP-1 side effect treatment progressJanuary 5, 2026 | investing.comRedHill Biopharma shares jump on progress toward treating GLP-1 side effectsJanuary 5, 2026 | msn.comRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side EffectsJanuary 5, 2026 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | finanznachrichten.deRedHill Biopharma announces in vivo results on opaganib, venetoclaxDecember 15, 2025 | msn.comRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant CellsDecember 15, 2025 | prnewswire.comRedHill Biopharma regains compliance with Nasdaq equity requirementDecember 1, 2025 | msn.comRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity RequirementDecember 1, 2025 | prnewswire.comRedHill Biopharma announces $10.5M New York Supreme Court judgment winNovember 4, 2025 | msn.comRedhill Biopharma stock jumps after court win against KukboNovember 4, 2025 | za.investing.comRedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for EnforcementNovember 4, 2025 | prnewswire.comRedHill Biopharma Appeals Nasdaq Delisting Notice After Equity BoostOctober 22, 2025 | msn.comRedHill Biopharma Receives Nasdaq Staff Determination NotificationOctober 22, 2025 | prnewswire.comRedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership DealOctober 21, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDHL, KZIA, KTTA, and CPHI Company DescriptionsChina Pharma NYSE:CPHI$0.53 +0.00 (+0.74%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Pasithea Therapeutics NASDAQ:KTTA$0.81 -0.03 (-3.21%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Novogen NASDAQ:KZIA$14.15 +0.74 (+5.49%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Redhill Biopharma NASDAQ:RDHL$1.00 -0.01 (-0.99%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
